This IDC Financial Insights Perspective takes a look at the challenges and opportunities of monetizing regulatory compliance spending. Regulatory compliance remains a focus for financial firms worldwide. Firms must maintain their staff and programs and continually search for new ways to maintain compliance monitoring and stay ahead of new threats, schemes, and criminal elements. Increasingly, IDC Financial Insights believes that firm managements will increase pressure on the firms' business and technology teams to find ways to monetize technology spending on regulatory and compliance programs as a way to recapture some of the compliance technology investments. Regulators are keeping up the pressure by adding new regulations and making compliance program reviews and inspections more detailed. For example, regulators are asking firms to see the data and the models firms are using for anti-money laundering (AML) transaction monitoring. As a result, firms are bolstering their AML transaction monitoring capabilities in an effort to stay ahead of new threats.
Our reports have been used by over 10K customers, including:
Introduction “Autism - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Autism . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API...
Introduction “Chronic Liver Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Chronic Liver Disease . The report includes information of marketed products including their product description, patent details,...
Introduction “Metastatic Prostate Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Metastatic Prostate Cancer . The report includes information of marketed products including their product description, patent...
Introduction “Lupus Nephritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Lupus Nephritis . The report includes information of marketed products including their product description, patent details, forecasted sales...
Introduction “Peripheral Neuropathic Pain - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Peripheral Neuropathic Pain . The report includes information of marketed products including their product description, patent...
Introduction “Soft Tissue Sarcoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Soft Tissue Sarcoma . The report includes information of marketed products including their product description, patent details, forecasted...
Introduction “Pyelonephritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Pyelonephritis . The report includes information of marketed products including their product description, patent details, forecasted sales...
This IDC Perspective examines recent changes to the commercialization and release model for Java SE and the implications of these changes for technology buyers of Java SE. "The complexity of the changes to Java SE is such that technology buyers could be forgiven for perceiving the new Java SE landscape as confusing and difficult to navigate....
This IDC Perspective discusses how concepts such as backup and recovery, disaster recovery (DR), and high availability (HA) are all vestiges of 2nd Platform technology. These capabilities are blending together into a continuum of application availability. As applications become available over a wide area, separate HA and DR infrastructure...
The global strategy consulting market accounted to US$43.07 Bn in 2017 and is expected to grow at a CAGR of 9.9% during the forecast period 2018 - 2025, to account to US$91.38 Bn by 2025. Strategy consulting is referred as strategic advisory or boardroom consulting, is considered by the majority of consultants as the most ’high-end’...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.